Search

Your search keyword '"Shimizu, Takuto"' showing total 200 results

Search Constraints

Start Over You searched for: Author "Shimizu, Takuto" Remove constraint Author: "Shimizu, Takuto"
200 results on '"Shimizu, Takuto"'

Search Results

1. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort

4. First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer

6. Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment–induced sleep quality deterioration in patients with non-muscle invasive bladder cancer

8. Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer

9. Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale

11. External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy

12. A Multicenter, Single-Arm, Prospective Trial to Evaluate Efficacy and Safety of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Carboplatin (DD-MVACarbo) Chemotherapy for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer: Study Protocol of the CARBUNCLE Trial

13. Photodynamic Therapeutic Effect during 5‐Aminolevulinic Acid‐Mediated Photodynamic Diagnosis‐Assisted Transurethral Resection of Bladder Tumors.

14. Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors

17. Long‐term follow‐up of congenital hydronephrosis in a single‐center study.

18. Machine Learning-based Gait Analysis to Predict Clinical Frailty Scale in Elderly Patients with Heart Failure

19. Assessment of diagnostic accuracy for cryptorchidism and risk factors for delayed orchidopexy

20. Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer

21. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma

22. Serum anandamide and lipids associated with linoleic acid can distinguish interstitial cystitis/bladder pain syndrome from overactive bladder: An exploratory study

23. Prognostic effect of the intensity of follow-up cystoscopy in patients with high-risk non-muscle invasive bladder cancer

25. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.

26. Assessment of diagnostic accuracy for cryptorchidism and risk factors for delayed orchidopexy.

27. Ganglioside GM3 deficiency enhances mast cell sensitivity

28. Clinical practice of UroVysion® urine test in patients with bladder carcinoma in situ treated with intravesical Bacillus Calmette–Guerin

29. PD05-11 SERUM ANANDAMIDE AND LIPIDS ASSOCIATED WITH LINOLEIC ACID CAN DISTINGUISH INTERSTITIAL CYSTITIS AND BLADDER PAIN SYNDROME FROM OVERACTIVE BLADDER

30. This title is unavailable for guests, please login to see more information.

31. MACHINE LEARNING-BASED AUTOMATIC RATING OF CLINICAL FRAILTY SCALE IN PATIENTS WITH HEART FAILURE: A PILOT STUDY

32. Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent

33. The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer

34. The novel sustained 3‐hydroxybutyrate donor poly‐D ‐3‐hydroxybutyric acid prevents inflammatory bowel disease through upregulation of regulatory T‐cells

35. Routine surveillance of upper urinary tract imaging for diagnosing upper urinary tract urothelial cancer recurrence in patients with non-muscle invasive bladder cancer having a tumor size ≥30 mm and carcinoma in situ.

36. Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study

38. Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer

39. Clinical significance of limited and extended pelvic lymph node dissection during robot‐assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis

40. Tumor expression of Nectin-1–4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression

43. Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study

44. Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data

46. Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.

47. Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.

48. Clinical significance of limited and extended pelvic lymph node dissection during robot‐assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis.

49. The novel sustained 3‐hydroxybutyrate donor poly‐D‐3‐hydroxybutyric acid prevents inflammatory bowel disease through upregulation of regulatory T‐cells.

50. Endothelial ganglioside GM3 regulates angiogenesis in solid tumors

Catalog

Books, media, physical & digital resources